What’s the current market cap for Revolution Medicines stock?

Revolution Medicines (RVMD) has a market cap of $33bn as of June 05, 2026.

What is the P/E ratio for Revolution Medicines stock?

The price to earnings (P/E) ratio for Revolution Medicines (RVMD) stock is 0 as of June 05, 2026.

Does Revolution Medicines stock pay dividends?

No, Revolution Medicines (RVMD) stock does not pay dividends to its shareholders as of June 05, 2026.

When is the next Revolution Medicines dividend payment date?

Revolution Medicines (RVMD) stock does not pay dividends to its shareholders.

What is the beta indicator for Revolution Medicines?

Revolution Medicines (RVMD) has a beta rating of 1.41. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Revolution Medicines stock | $RVMD Share Price

13:30

15:10

16:45

18:25

20:00

About Revolution Medicines

Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

Ticker

$RVMD

Sector

Health

Primary listing

NASDAQ

Employees

883

Headquarters

Redwood City, United States

Website

www.revmed.com

RVMD Metrics

BasicAdvanced

$33bn

-$7.12

1.41

What the Analysts think about RVMD

Analyst ratings (Buy, Hold, Sell) for Revolution Medicines stock.

Bulls say / Bears say

The FDA granted early access to daraxonrasib for previously treated pancreatic cancer after a trial showed it doubled patient survival compared to chemotherapy, highlighting the drug's clinical advantage (Reuters).

Mizuho analysts project that Revolution’s RAS inhibitor portfolio could achieve risk-adjusted sales exceeding $10 billion by 2035, showcasing significant long-term commercial potential (Reuters).

Merck’s reported acquisition talks with Revolution, valuing the company at up to $32 billion, underscore strategic interest and confirm the value of Revolution's robust RAS(ON) inhibitor pipeline (Reuters).

2026 GAAP operating expense guidance was raised to $1.7–$1.8 billion, signaling a quarterly cash burn of more than $400 million and potential need for additional equity or debt financing (SEC 8-K).

Revolution Medicines posted a Q1 2026 EPS loss of $2.29, missing the consensus estimate of $1.83 by $0.46, due to higher-than-expected R&D and commercial expenses (MarketBeat).

Needham lowered its 12-month price target on RVMD to $183 from $186, citing higher non-cash compensation and operating expense pressures, indicating limited near-term upside (Investing.com).

Data summarised monthly by Lightyear AI. Last updated on 21 May 2026.

RVMD Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

RVMD Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RVMD

Capital at risk

Market closed

Upcoming events

No upcoming events